Drug: Acalabrutinib (AstraZeneca/Acerta Pharma)
Status: Granted breakthrough therapy designation for treatment of patients with mantle cell lymphoma (MCL) who have received at least one previous therapy
Significant Information:
- Acalabrutinib is a highly selective, potent Bruton tyrosine kinase (BTK) inhibitor
- Under development for treatment of multiple B-cell cancers
- Data on use of acalabrutinib collected through a Phase II ACE-LY-004 clinical trial conducted with patients who have relapsed or